18F-Flortaucipir in TDP-43 associated frontotemporal dementia

Retention of 18F-Flortaucipir is reportedly increased in the semantic variant of primary progressive aphasia (svPPA), which is dominated by TDP-43 pathology. However, it is unclear if 18F-Flortaucipir is also increased in other TDP-43 diseases, such as bvFTD caused by a C9orf72 gene mutation. We therefore recruited six C9orf72 expansion carriers, six svPPA patients, and 54 healthy controls. All underwent 18F-Flortaucipir PET and MRI scanning. Data from 39 Alzheimer’s Disease patients were used for comparison. PET tracer retention was assessed both at the region-of-interest (ROI) and at the voxel-level. Further, autoradiography using 3H-Flortaucipir was performed. SvPPA patients exhibited higher 18F-Flortaucipir retention in the lateral temporal cortex bilaterally according to ROI- and voxel-based analyses. In C9orf72 patients, 18F-Flortaucipir binding was slightly increased in the inferior frontal lobes in the ROI based analysis, but these results were not replicated in the voxel-based analysis. Autoradiography did not show specific binding in svPPA cases or in C9orf72-mutation carriers. In conclusion, temporal lobe 18F-Flortaucipir retention was observed in some cases of svPPA, but the uptake was of a lower magnitude compared to AD dementia. C9orf72-mutation carriers exhibited none or limited 18F-Flortaucipir retention, indicating that 18F-Flortaucipir binding in TDP-43 proteinopathies is not a general TDP-43 related phenomenon.

[1]  Rik Ossenkoppele,et al.  Distinct 18F‐AV‐1451 tau PET retention patterns in early‐ and late‐onset Alzheimer's disease , 2017, Brain : a journal of neurology.

[2]  S. Gauthier,et al.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.

[3]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[4]  John R Hodges,et al.  New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  O. Hansson,et al.  18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers , 2016, Brain : a journal of neurology.

[6]  Keith A. Johnson,et al.  Flortaucipir tau PET imaging in semantic variant primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[7]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[8]  Ming-Rong Zhang,et al.  PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.

[9]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[10]  D. Yves von Cramon,et al.  Towards a nosology for frontotemporal lobar degenerations—A meta-analysis involving 267 subjects , 2007, NeuroImage.

[11]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[12]  D. Mann,et al.  Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype , 2017, Brain pathology.

[13]  Nick C Fox,et al.  Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features , 2012, Alzheimer's & Dementia.

[14]  D. Brooks,et al.  MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding , 2018, Molecular Imaging and Biology.

[15]  T. Ferman,et al.  Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72 , 2011, Acta Neuropathologica.

[16]  H. Arai,et al.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[17]  D. J. Brooks,et al.  Tau imaging in neurodegenerative diseases , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[19]  E. Londos,et al.  18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies , 2018, Scientific Reports.

[20]  W. Jagust,et al.  Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data , 2017, Data in brief.

[21]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[22]  Rupert Lanzenberger,et al.  Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology , 2017, The Journal of Nuclear Medicine.

[23]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[24]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[25]  K. Blennow,et al.  Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment , 2017, JAMA neurology.

[26]  B. Miller,et al.  Typical and atypical pathology in primary progressive aphasia variants , 2017, Annals of neurology.

[27]  Bradford C. Dickerson,et al.  Tau PET imaging in aging and early Alzheimer's disease , 2015 .

[28]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[29]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[30]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  G. Rabinovici,et al.  Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. , 2016, Journal of Alzheimer's disease : JAD.

[32]  Luca Passamonti,et al.  [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[33]  D. Mann,et al.  Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72 , 2014, Acta neuropathologica communications.

[34]  Young T. Hong,et al.  [18F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion , 2018, Annals of clinical and translational neurology.

[35]  J. Trojanowski,et al.  A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.

[36]  J. Hodges,et al.  Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. , 2010, Brain : a journal of neurology.

[37]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[38]  G. Berglund,et al.  The Malmö diet and cancer study: representativity, cancer incidence and mortality in participants and non‐participants , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[39]  Henrik Zetterberg,et al.  Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity , 2017, Nature Communications.

[40]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[41]  Philip Scheltens,et al.  The clinical profile of right temporal lobe atrophy. , 2004, Brain : a journal of neurology.

[42]  Nick C Fox,et al.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.